Cover Image
市場調查報告書

病毒惰性化的全球市場預測 2021年:幹細胞產品、血液製劑、細胞組織產品、細胞療法、遺傳基因療法

Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization), End User (Pharmaceutical & Biotechnology, CROs) - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 361359
出版日期 內容資訊 英文 155 Pages
訂單完成後即時交付
價格
Back to Top
病毒惰性化的全球市場預測 2021年:幹細胞產品、血液製劑、細胞組織產品、細胞療法、遺傳基因療法 Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization), End User (Pharmaceutical & Biotechnology, CROs) - Global Forecast to 2021
出版日期: 2016年06月06日 內容資訊: 英文 155 Pages
簡介

全球病毒惰性化市場,預計從2016到2020年以12.3%的年複合成長率發展,從2016年的3億2,050萬美元,到2021年達到5億7,300萬美元。該市場的主要促進成長因素,是醫藥品、生技藥品產業的擴大及新藥銷售數的增加等。

本報告以病毒惰性化的全球市場為焦點,提供各處理法、產品、應用、終端用戶,及各地區預測,市場現狀,發展的影響要素,競爭環境,主要企業等相關的調查、分析資訊彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 應特別記載考察點

  • 全球病毒惰性化市場概要
  • 生命週期分析:各地區

第5章 市場概要

  • 簡介
    • 市場區隔
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會
    • 課題

第6章 病毒惰性化市場:各處理法

  • 簡介
  • S/D(有機溶媒/界面活性劑) 處理法
  • 殺菌處理
  • 其他技術

第7章 病毒惰性化市場:各產品

  • 簡介
  • 套件、試劑
  • 服務
  • 病毒惰性化系統、飾品

第8章 病毒惰性化市場:各應用領域

  • 簡介
  • 疫苗、治療藥
  • 血液、血液製劑
  • 細胞療法、遺傳基因療法產品
  • 細胞組織、細胞組織產品
  • 幹細胞產品

第9章 病毒惰性化市場:各終端用戶

  • 簡介
  • 醫藥品、生物科技企業
  • CRO (醫藥品臨床研究委外機構)
  • 大學研究機關
  • 其他終端用戶

第10章 病毒惰性化市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞洲
  • 其他 (RoW)

第11章 競爭情形

  • 概要
  • 策略概要
  • 主要企業
  • 競爭情形、趨勢

第12章 企業簡介 (簡介、產品&服務、策略&考察、近幾年的發展趨勢、MNM的見解)

  • 簡介
  • DANAHER CORPORATION
  • MERCK KGAA
  • PARKER HANNIFIN CORPORATION 126
  • SARTORIUS AG
  • SGS SA
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • CLEAN CELLS INC.
  • RAD SOURCE TECHNOLOGIES, INC.
  • TEXCELL, INC.
  • VIRAL INACTIVATED PLASMA SYSTEMS SA
  • WUXI PHARMATECH (CAYMAN) INC.

第13章 附錄

目錄
Product Code: BT 4361

The global viral inactivation market is projected to reach USD 573.0 million by 2021 from USD 320.5 million in 2016, at a CAGR of 12.3% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of new drug launches. Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA's Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the viral inactivation market.

According to OECD estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.

This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.

The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.

The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.

Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users.

The geographic segments included in this report are Asia, Europe, North America and the Rest of the World (RoW). North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.

The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

  • Product Development/Innovation: Product portfolios of top players in the viral inactivation market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the viral inactivation market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the viral inactivation market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various viral inactivation products across geographies
  • Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the viral inactivation market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED FOR THE STUDY
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.3. MARKET SHARE ESTIMATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. GLOBAL VIRAL INACTIVATION MARKET OVERVIEW
  • 4.2. LIFE CYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
    • 5.1.1. MARKET SEGMENTATION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Rapid growth in pharmaceutical and biotechnology industries
      • 5.2.1.2. Increasing number of new drug launches
      • 5.2.1.3. Strong R&D investments in the life sciences industry
      • 5.2.1.4. Increasing government support for pharmaceutical and biotechnology industries
      • 5.2.1.5. High incidence and large economic burden of chronic diseases
    • 5.2.2. RESTRAINT
      • 5.2.2.1. High degree of consolidation to act as a major barrier for new entrants
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Increasing pharmaceutical outsourcing
      • 5.2.3.2. Developing countries present significant growth opportunities for the viral inactivation market
    • 5.2.4. CHALLENGE
      • 5.2.4.1. Stringent regulatory frameworks and time-consuming approval processes for viral inactivation products

6. VIRAL INACTIVATION MARKET, BY METHOD

  • 6.1. INTRODUCTION
  • 6.2. SOLVENT DETERGENT METHOD
  • 6.3. PASTEURIZATION
  • 6.4. OTHER METHODS

7. VIRAL INACTIVATION MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. KITS AND REAGENTS
  • 7.3. SERVICES
  • 7.4. VIRAL INACTIVATION SYSTEMS AND ACCESSORIES

8. VIRAL INACTIVATION MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. VACCINES AND THERAPEUTICS
  • 8.3. BLOOD AND BLOOD PRODUCTS
  • 8.4. CELLULAR AND GENE THERAPY PRODUCTS
  • 8.5. TISSUES AND TISSUE PRODUCTS
  • 8.6. STEM CELL PRODUCTS

9. VIRAL INACTIVATION MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 9.3. CONTRACT RESEARCH ORGANIZATIONS
  • 9.4. ACADEMIC RESEARCH INSTITUTES
  • 9.5. OTHER END USERS

10. VIRAL INACTIVATION MARKET, BY GEOGRAPHY

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA
  • 10.5. REST OF THE WORLD

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. STRATEGIC OVERVIEW
  • 11.3. LEADING PLAYERS IN THE VIRAL INACTIVATION MARKET
  • 11.4. COMPETITIVE SITUATION AND TRENDS
    • 11.4.1. EXPANSIONS
    • 11.4.2. ACQUISITIONS
    • 11.4.3. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 11.4.4. SERVICES LAUNCHES

12. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. DANAHER CORPORATION
  • 12.3. MERCK KGAA
  • 12.4. PARKER HANNIFIN CORPORATION
  • 12.5. SARTORIUS AG
  • 12.6. SGS SA
  • 12.7. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • 12.8. CLEAN CELLS INC.
  • 12.9. RAD SOURCE TECHNOLOGIES, INC.
  • 12.10. TEXCELL, INC.
  • 12.11. VIRAL INACTIVATED PLASMA SYSTEMS SA
  • 12.12. WUXI PHARMATECH (CAYMAN) INC.

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. OTHER DEVELOPMENTS
  • 13.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.6. AVAILABLE CUSTOMIZATIONS
  • 13.7. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: VIRAL INACTIVATION MARKET SUMMARY
  • TABLE 2: RAPID GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES DRIVING THE GROWTH OF THE VIRAL INACTIVATION MARKET
  • TABLE 3: HIGH DEGREE OF CONSOLIDATION TO RESTRICT ENTRY OF NEW PLAYERS
  • TABLE 4: INCREASING PHARMACEUTICAL OUTSOURCING TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE VIRAL INACTIVATION MARKET
  • TABLE 5: STRINGENT REGULATORY FRAMEWORKS FOR VIRAL INACTIVATION PRODUCTS ARE A MAJOR MARKET CHALLENGE
  • TABLE 6: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 7: VIRAL INACTIVATION MARKET SIZE FOR SOLVENT DETERGENT METHOD, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: VIRAL INACTIVATION MARKET SIZE FOR PASTEURIZATION METHOD, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: VIRAL INACTIVATION MARKET SIZE FOR OTHER METHODS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 11: VIRAL INACTIVATION KITS AND REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: VIRAL INACTIVATION SERVICES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: VIRAL INACTIVATION SYSTEMS AND ACCESSORIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 15: VIRAL INACTIVATION MARKET SIZE FOR VACCINES AND THERAPEUTICS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: VIRAL INACTIVATION MARKET SIZE FOR BLOOD AND BLOOD PRODUCTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: VIRAL INACTIVATION MARKET SIZE FOR CELLULAR AND GENE THERAPY PRODUCTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: VIRAL INACTIVATION MARKET SIZE FOR TISSUES AND TISSUE PRODUCTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: VIRAL INACTIVATION MARKET SIZE FOR STEM CELL PRODUCTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 21: VIRAL INACTIVATION MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: VIRAL INACTIVATION MARKET SIZE FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: VIRAL INACTIVATION MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: VIRAL INACTIVATION MARKET SIZE FOR OTHER END USERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: VIRAL INACTIVATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 28: NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 29: NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 31: U.S.: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 32: U.S.: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 33: U.S.: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 34: U.S.: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 35: CANADA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 36: CANADA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 37: CANADA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 38: CANADA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 39: EUROPE: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 40: EUROPE: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 41: EUROPE: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 42: EUROPE: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 43: ASIA: VIRAL INACTIVATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 44: ASIA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 45: ASIA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 46: ASIA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 47: ASIA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 48: CHINA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 49: CHINA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 50: CHINA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 51: CHINA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 52: JAPAN: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 53: JAPAN: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 54: JAPAN: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 55: JAPAN: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 56: INDIA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 57: INDIA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 58: INDIA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 59: INDIA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 60: ROA: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 61: ROA: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 62: ROA: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 63: ROA: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 64: ROW: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 65: ROW: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 66: ROW: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION)
  • TABLE 67: ROW: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 68: MARKET DEVELOPMENTS BETWEEN 2012 AND 2016
  • TABLE 69: EXPANSIONS, 2012-2016
  • TABLE 70: ACQUISITIONS, 2012-2016
  • TABLE 71: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012-2016
  • TABLE 72: SERVICES LAUNCHES, 2012-2015

LIST OF FIGURES

  • FIGURE 1: GLOBAL VIRAL INACTIVATION MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: VIRAL INACTIVATION MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2016 VS. 2021 (USD MILLION)
  • FIGURE 10: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 11: VIRAL INACTIVATION MARKET SIZE, BY REGION, 2016 VS. 2021 USD MILLION)
  • FIGURE 12: GROWTH IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES WILL DRIVE THE VIRAL INACTIVATION MARKET DURING THE FORECAST PERIOD (2016-2021)
  • FIGURE 13: KITS AND REAGENTS PRODUCT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016
  • FIGURE 14: ASIA TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • FIGURE 15: ASIA HOLDS LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 16: VIRAL INACTIVATION MARKET SEGMENTATION
  • FIGURE 17: VIRAL INACTIVATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 18: NUMBER OF NEW PHARMACEUTICAL DRUG LAUNCHED, 2003-2013
  • FIGURE 19: VIRAL INACTIVATION MARKET SIZE, BY METHOD, 2016 (USD MILLION)
  • FIGURE 20: NORTH AMERICA TO DOMINATE THE SOLVENT DETERGENT METHOD SEGMENT IN 2016
  • FIGURE 21: NORTH AMERICA TO DOMINATE THE PASTEURIZATION SEGMENT IN 2016
  • FIGURE 22: NORTH AMERICA TO DOMINATE THE OTHER METHODS SEGMENT IN 2016
  • FIGURE 23: KITS AND REAGENTS TO FORM THE LARGEST PRODUCT SEGMENT IN 2016
  • FIGURE 24: NORTH AMERICA TO DOMINATE THE VIRAL INACTIVATION KITS AND REAGENTS MARKET IN 2016
  • FIGURE 25: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION SERVICES MARKET IN 2016
  • FIGURE 26: NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION SYSTEMS AND ACCESSORIES MARKET IN 2016
  • FIGURE 27: VIRAL INACTIVATION MARKET SIZE, BY APPLICATION, 2016 (USD MILLION)
  • FIGURE 28: NORTH AMERICA TO DOMINATE THE VACCINES AND THERAPEUTICS SEGMENT IN 2016
  • FIGURE 29: NORTH AMERICA HOLDS THE LARGEST SHARE IN THE BLOOD AND BLOOD PRODUCTS SEGMENT IN 2016
  • FIGURE 30: ASIA TO WITNESS HIGHEST GROWTH IN THE CELLULAR AND GENE THERAPY PRODUCTS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 31: NORTH AMERICA TO COMMAND LARGEST SHARE OF THE TISSUES AND TISSUE PRODUCTS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 32: ASIA TO WITNESS HIGHEST GROWTH IN THE STEM CELL PRODUCTS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 33: VIRAL INACTIVATION MARKET, BY END USER
  • FIGURE 34: VIRAL INACTIVATION MARKET SIZE, BY END USER, 2016 (USD MILLION)
  • FIGURE 35: NORTH AMERICA TO DOMINATE THE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES END-USER SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 36: ASIA TO WITNESS THE HIGHEST GROWTH IN THE CONTRACT RESEARCH ORGANIZATION END-USER SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 37: ASIA TO WITNESS THE HIGHEST GROWTH IN THE ACADEMIC RESEARCH INSTITUTES END-USER SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 38: NORTH AMERICA TO DOMINATE THE OTHER END USERS SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 39: NORTH AMERICA TO DOMINATE THE GLOBAL VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 40: ASIAN VIRAL INACTIVATION MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2016-2021)
  • FIGURE 41: NORTH AMERICA: VIRAL INACTIVATION MARKET SNAPSHOT
  • FIGURE 42: U.S. TO WITNESS HIGHEST GROWTH IN THE NORTH AMERICAN VIRAL INACTIVATION MARKET DURING THE FORECAST PERIOD (2016-2021)
  • FIGURE 43: VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 44: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE NORTH AMERICAN VIRAL INACTIVATION END-USER MARKET IN 2016
  • FIGURE 45: SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE NORTH AMERICAN MARKET IN 2016
  • FIGURE 46: KITS AND REAGENTS ESTIMATED TO FORM THE LARGEST PRODUCT SEGMENT IN THE NORTH AMERICAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 47: VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE EUROPEAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 48: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE EUROPEAN VIRAL INACTIVATION END-USERS MARKET IN 2016
  • FIGURE 49: SOLVENT DETERGENT METHODS SEGMENT TO DOMINATE THE VIRAL INACTIVATION MARKET IN EUROPE IN 2016
  • FIGURE 50: KITS AND REAGENTS TO FORM THE LARGEST PRODUCT SEGMENT IN THE EUROPEAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 51: ASIA: VIRAL INACTIVATION MARKET SNAPSHOT
  • FIGURE 52: CHINA TO WITNESS HIGHEST GROWTH IN THE ASIAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 53: VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE ASIAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 54: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE ASIAN VIRAL INACTIVATION END-USERS MARKET IN 2016
  • FIGURE 55: SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE ASIAN MARKET IN 2016
  • FIGURE 56: KITS AND REAGENTS ESTIMATED TO FORM THE LARGEST PRODUCT SEGMENT IN THE ASIAN VIRAL INACTIVATION MARKET IN 2016
  • FIGURE 57: VACCINES AND THERAPEUTICS SEGMENT TO COMMAND THE LARGEST SHARE OF THE VIRAL INACTIVATION MARKET IN THE REST OF THE WORLD IN 2016
  • FIGURE 58: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DOMINATE THE VIRAL INACTIVATION END-USERS MARKET IN THE REST OF THE WORLD IN 2016
  • FIGURE 59: SOLVENT DETERGENT METHOD SEGMENT TO DOMINATE THE VIRAL INACTIVATION MARKET IN THE REST OF THE WORLD REGION IN 2016
  • FIGURE 60: KITS AND REAGENTS TO FORM THE LARGEST VIRAL INACTIVATION PRODUCT SEGMENT IN THE REST OF THE WORLD REGION IN 2016
  • FIGURE 61: EXPANSIONS AND ACQUISITIONS-KEY STRATEGIES ADOPTED BY PLAYERS
  • FIGURE 62: VIRAL INACTIVATION MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
  • FIGURE 63: FINANCIAL PERFORMANCE OF LEADING MARKET PLAYERS (2013-2015)
  • FIGURE 64: COMPANY SNAPSHOT: DANAHER CORPORATION
  • FIGURE 65: COMPANY SNAPSHOT: MERCK KGAA
  • FIGURE 66: COMPANY SNAPSHOT: PARKER HANNIFIN CORPORATION
  • FIGURE 67: COMPANY SNAPSHOT: SARTORIUS AG
  • FIGURE 68: COMPANY SNAPSHOT: SGS SA
  • FIGURE 69: COMPANY SNAPSHOT: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • FIGURE 70: COMPANY SNAPSHOT: WUXI PHARMATECH (CAYMAN) INC.
Back to Top